The financials
McKesson Corporation by the numbers
McKesson Corporation (MCK) reported revenue of $96.3B in Q4 2026 (quarter ended March 31, 2026), up 6.0% from the same quarter a year earlier. That came with a gross margin of 4.2% and net income of $1.68B (1.7% of revenue). For the full year FY2026, revenue was $403.4B (+12% year on year) and net income $4.76B. Its largest segment in 2025-Q4 was North American Pharmaceutical at $88.3B, 83% of the disclosed total, just ahead of Oncology And Multispecialty at 12%.
| Income statement | Q4 2026 | Q4 2025 | Change |
|---|---|---|---|
| Revenue | $96.3B | $90.8B | +6.0% |
| Gross profit | $4.04B | $3.64B | +11% |
| Operating income | $2.15B | $1.59B | +35% |
| Net income | $1.68B | $1.26B | +33% |
| Diluted EPS | $13.65 | $9.92 | +38% |
| Operating | Revenue | Share |
|---|---|---|
| North American Pharmaceutical | $88.3B | 83% |
| Oncology And Multispecialty | $13.0B | 12% |
| Medical Surgical Solutions | $2.99B | 2.8% |
| Prescription Technology Solutions | $1.50B | 1.4% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q4 2025Total $105.82B (+2.9%)
Oncology And Multispecialty grew +37% year on yearMedical Surgical Solutions +1.4% year on year
Segment Latestquarter on quarteryear on year
- North American Pharmaceutical$88.32B$88.32BQoQ +2.1%year on year +8.8%+2.1%+8.8%
- Oncology And Multispecialty$13.01B$13.01BQoQ +8.0%year on year +37%+8.0%+37%
- Medical Surgical Solutions$2.99B$2.99BQoQ +1.5%year on year +1.4%+1.5%+1.4%
- Prescription Technology Solutions$1.50B$1.50BQoQ +9.0%year on year +9.4%+9.0%+9.4%
- Corporate--QoQ -year on year ---
- International--QoQ -year on year ---
- US Pharmaceutical--QoQ -year on year ---
Healthcare
Ranks #240 of 345 by Smart Score